Vivani Medical (VANI) said Thursday that it has completed enrolling participants in its initial clinical trial testing NPM-115, a subdermal GLP-1 implant for overweight adults with type 2 diabetes.
The company said the first patient received the implant as part of the study, which is designed to evaluate drug absorption and safety over a six-month period.
Vivani said the enrollment concluded about four weeks after the first subject was dosed, with preliminary results expected by mid-2025.
The company's shares were up more than 2% in recent Thursday premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.